NasdaqCM - Delayed Quote USD

Alzamend Neuro, Inc. (ALZN)

0.7195 -0.0065 (-0.90%)
At close: April 26 at 4:00 PM EDT
0.7500 +0.03 (+4.24%)
After hours: April 26 at 6:29 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
4/30/2023
4/30/2022
4/30/2021
4/30/2020
Operating Expense
15,156.1730
14,870.4660
12,319.5350
4,951.8880
4,424.1610
Operating Income
-15,156.1730
-14,870.4660
-12,319.5350
-4,951.8880
-4,424.1610
Net Non Operating Interest Income Expense
-8.7280
-7.7010
-46.5240
-157.0970
13.9250
Other Income Expense
--
--
4.0000
62.4180
--
Pretax Income
-15,164.9010
-14,878.1670
-12,362.0590
-5,046.5670
-4,410.2360
Net Income Common Stockholders
-15,164.9010
-14,878.1670
-12,362.0590
-5,046.5670
-4,410.2360
Diluted NI Available to Com Stockholders
-15,164.9010
-14,878.1670
-12,362.0590
-5,046.5670
-4,410.2360
Basic EPS
-1.82
-2.25
-2.10
-0.89
-0.74
Diluted EPS
-1.82
-2.25
-2.10
-0.89
-0.74
Basic Average Shares
6,658.1880
6,501.2670
5,939.6840
5,661.9680
5,984.1900
Diluted Average Shares
6,658.1880
6,501.2670
5,939.6840
5,661.9680
5,984.1900
Total Operating Income as Reported
-15,156.1730
-14,870.4660
-12,319.5350
-4,951.8880
-4,424.1610
Total Expenses
15,156.1730
14,870.4660
12,319.5350
4,951.8880
4,424.1610
Net Income from Continuing & Discontinued Operation
-15,164.9010
-14,878.1670
-12,362.0590
-5,046.5670
-4,410.2360
Normalized Income
-15,164.9010
-14,878.1670
-12,366.0590
-5,108.9850
-4,410.2360
Interest Income
--
--
--
1.7060
13.9250
Interest Expense
8.7280
7.7010
46.5240
158.8030
--
Net Interest Income
-8.7280
-7.7010
-46.5240
-157.0970
13.9250
EBIT
-15,156.1730
-14,870.4660
-12,315.5350
-4,887.7640
-4,410.2360
EBITDA
-15,120.1570
-14,847.4000
-12,311.9860
-4,887.7640
-4,410.2360
Reconciled Depreciation
36.0160
23.0660
3.5490
--
--
Net Income from Continuing Operation Net Minority Interest
-15,164.9010
-14,878.1670
-12,362.0590
-5,046.5670
-4,410.2360
Total Unusual Items Excluding Goodwill
--
--
4.0000
62.4180
--
Total Unusual Items
--
--
4.0000
62.4180
--
Normalized EBITDA
-15,120.1570
-14,847.4000
-12,315.9860
-4,950.1820
-4,410.2360
4/30/2020 - 6/15/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BCDA BioCardia, Inc.
0.3766
+2.95%
 
AZTR Azitra, Inc.
0.2185
-0.73%
 
ENSC Ensysce Biosciences, Inc.
0.5842
+1.69%
 
SMMT Summit Therapeutics Inc.
3.8600
+8.73%
 
FNCH Finch Therapeutics Group, Inc.
2.3200
+3.11%
 
ATHE Alterity Therapeutics Limited
2.5100
+9.61%
 
KA Kineta, Inc.
0.6100
-2.37%
 
LIPO Lipella Pharmaceuticals Inc.
0.7110
+0.98%
 
KZIA Kazia Therapeutics Limited
0.3700
+1.43%
 
FBRX Forte Biosciences, Inc.
0.7163
-0.07%